Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Novartis’ Glivec Hearing Approaches, Indian IP Panel Adds Court-Ordered Technical Member

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Swiss pharma giant Novartis is "pleased" with the appointment of a new technical member to an Indian panel hearing a high-profile challenge by Novartis regarding the rejection of patent protection for its blockbuster leukemia drug Glivec

You may also be interested in...

A Closer Look: India Patent Disputes Heat Up For Big Pharma

MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions

Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India

By: Shamnad Basheer

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts